Search research articles
Contact Us
Filters
Showing results (1-10 of 9) with videos related to
Page
of 1
Sort By:
Biomed Research International
|
January 29, 2019
Transarterial Radioembolization (TARE) Agents beyond <sup>90</sup>Y-Microspheres
C Bouvry, X Palard, J Edeline, et al.
EJNMMI Research
|
September 20, 2019
Voxel-based identification of local recurrence sub-regions from pre-treatment PET/CT for locally advanced head and neck cancers
J Beaumont, O Acosta, A Devillers, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique
|
September 8, 2022
Head and neck cancers volume reduction: should we reduce our prophylactic node radiation to spare the antitumor immune response?
Y El Houat, L Bouvier, M Baty, et al.
Cancer Medicine
|
December 16, 2024
Assessment and Prediction of Salivary Gland Function After Head and Neck Radiotherapy: A Systematic Review
J Le Guevelou, X Palard-Novello, E Kammerer, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique
|
August 19, 2019
Salvage reirradiation for local prostate cancer recurrence after radiation therapy. For who? When? How?
M Baty, G Créhange, D Pasquier, et al.
Journal of Neurology
|
July 28, 2019
Postural instability and gait disorders after subthalamic nucleus deep brain stimulation in Parkinson's disease: a PET study
Kévin Ahrweiller, J F Houvenaghel, A Riou, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
January 13, 2016
Value of (18)F-FDG PET/CT for therapeutic assessment of patients with polymyalgia rheumatica receiving tocilizumab as first-line treatment
X Palard-Novello, S Querellou, M Gouillou, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
September 18, 2023
Baseline [<sup>18</sup>F]FDG PET features are associated with survival and toxicity in patients treated with CAR T cells for large B cell lymphoma
E Marchal, X Palard-Novello, F Lhomme, et al.
Immuno-Oncology Technology
|
January 8, 2026
Phase I(b) study evaluating the safety and efficacy of intratumoral agonistic anti-CD40 (selicrelumab) in combination with anti-PD-L1 (atezolizumab) in patients with refractory or relapsed B-cell lymphoma (ITSELF trial)
N Alshatti, F Lemonnier, E Bachy, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 9) with videos related to
Sort By:
Page
of 1
Biomed Research International
|
January 29, 2019
Transarterial Radioembolization (TARE) Agents beyond <sup>90</sup>Y-Microspheres
C Bouvry, X Palard, J Edeline, et al.
EJNMMI Research
|
September 20, 2019
Voxel-based identification of local recurrence sub-regions from pre-treatment PET/CT for locally advanced head and neck cancers
J Beaumont, O Acosta, A Devillers, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique
|
September 8, 2022
Head and neck cancers volume reduction: should we reduce our prophylactic node radiation to spare the antitumor immune response?
Y El Houat, L Bouvier, M Baty, et al.
Cancer Medicine
|
December 16, 2024
Assessment and Prediction of Salivary Gland Function After Head and Neck Radiotherapy: A Systematic Review
J Le Guevelou, X Palard-Novello, E Kammerer, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique
|
August 19, 2019
Salvage reirradiation for local prostate cancer recurrence after radiation therapy. For who? When? How?
M Baty, G Créhange, D Pasquier, et al.
Journal of Neurology
|
July 28, 2019
Postural instability and gait disorders after subthalamic nucleus deep brain stimulation in Parkinson's disease: a PET study
Kévin Ahrweiller, J F Houvenaghel, A Riou, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
January 13, 2016
Value of (18)F-FDG PET/CT for therapeutic assessment of patients with polymyalgia rheumatica receiving tocilizumab as first-line treatment
X Palard-Novello, S Querellou, M Gouillou, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
September 18, 2023
Baseline [<sup>18</sup>F]FDG PET features are associated with survival and toxicity in patients treated with CAR T cells for large B cell lymphoma
E Marchal, X Palard-Novello, F Lhomme, et al.
Immuno-Oncology Technology
|
January 8, 2026
Phase I(b) study evaluating the safety and efficacy of intratumoral agonistic anti-CD40 (selicrelumab) in combination with anti-PD-L1 (atezolizumab) in patients with refractory or relapsed B-cell lymphoma (ITSELF trial)
N Alshatti, F Lemonnier, E Bachy, et al.
Page
of 1